Here’s a groundbreaking development that could save countless lives: a new typhoid conjugate vaccine has proven its mettle in a Phase III trial, showing remarkable safety and effectiveness in regions where typhoid is a persistent threat. But here’s where it gets controversial—while the vaccine’s success is undeniable, its accessibility and affordability in low-income countries remain a hotly debated topic. Let’s dive into the details.
The Phase III trial of EuTYPH-C Inj. Multi-dose, a typhoid conjugate vaccine (TCV) developed by EuBiologics Co., LTD in the Republic of Korea, has delivered promising results. Conducted in Kenya and Senegal, the study involved 3,219 healthy participants aged 6 months to 45 years, including adults, children, and infants. Published in The Lancet Global Health, the research demonstrated that the vaccine is not only safe but also highly immunogenic in populations living in typhoid-endemic areas of sub-Saharan Africa.
And this is the part most people miss—the vaccine was tested alongside other childhood vaccines, such as measles-rubella and yellow fever, at 9–12 months of age, and it showed no interference with the immune responses to these other pathogens. This is a game-changer for immunization programs, as it simplifies the vaccination process for children in high-risk regions.
Patricia Njuguna, Senior Medical Officer and project lead from PATH, emphasized, 'Safety is non-negotiable when it comes to vaccines. EuTYPH-C Inj. Multi-dose was well-tolerated across all age groups, with a safety profile comparable to the established Typbar TCV. No serious adverse events were reported, which is a significant achievement.'
Immunogenicity, the vaccine’s ability to trigger a robust immune response, was assessed in participants aged 9 to 12 months. Both single-dose and multi-dose versions of EuTYPH-C Inj. Multi-dose performed on par with Typbar TCV, meeting the criteria for noninferiority. Seroconversion rates—the proportion of individuals developing antibodies—were impressively high at 28 days post-vaccination and remained stable even six months later.
Here’s the bold part: With these results, EuTYPH-C Inj. Multi-dose has secured licensure from the Korean Ministry of Food and Drug Safety and is now aiming for WHO prequalification. This designation is crucial, as it ensures the vaccine meets global standards for quality, safety, and efficacy, making it eligible for procurement by United Nations agencies and Gavi, the Vaccine Alliance. But the question remains: Will this vaccine reach those who need it most, or will it become another tool out of reach for the poorest nations?
Currently, there are four prequalified TCVs, with two available for Gavi-eligible countries. The introduction of EuTYPH-C Inj. Multi-dose could help lower vaccine prices, stabilize supply, and expand access. Dr. Emmanuel Mugisha, Global Director for Vaccine Implementation at PATH, noted, 'The demand for TCVs in typhoid-endemic countries is skyrocketing. An additional product like this could be a lifeline for nations struggling to control typhoid outbreaks.'
However, the journey isn’t without challenges. While seven Gavi-eligible countries have already introduced TCVs, many others are still navigating the complexities of planning and implementation. The success of this vaccine hinges not just on its scientific achievements but on global commitment to equitable distribution.
Now, here’s a thought-provoking question for you: With the potential to save millions from typhoid, should vaccines like EuTYPH-C Inj. Multi-dose be prioritized for mass production and distribution, even if it means diverting resources from other health initiatives? Let us know your thoughts in the comments below.
This study was a collaborative effort involving PATH, EuBiologics Co., LTD, the Kenya Medical Research Institute (KEMRI)-Walter Reed Army Institute of Research (WRAIR) Kericho, and the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF). For more details, you can explore the full study here.
Provided by PATH. This content is for informational purposes only and is subject to copyright. Reproduction without permission is prohibited.
